Influence of macrolide antibiotics on promotion of resistance in the oral flora of children

被引:67
作者
Kastner, U [1 ]
Guggenbichler, JP [1 ]
机构
[1] Univ Erlangen Nurnberg, Dept Pediat Infect Dis, Univ Clin Pediat & Adolescent Patients, D-91054 Erlangen, Germany
关键词
macrolides; azithromycin; resistance; oral flora;
D O I
10.1007/s15010-001-1072-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The tong elimination half-life of azithromycin allows subinhibitory serum and epithelial Lining fluid (ELF) concentrations over a period of several weeks post treatment, which may have an impact on the emergence of macrolide resistance. In this prospective, open-label, randomized study, four macrolides and the azalide azithromycin were studied for their Likelihood to promote resistance in the oral flora of children with respiratory tract infections. Patients and Methods: Children were randomly assigned to receive azithromycin, clarithromycin, erythromycin, roxithromycin and josamycin. Throat swabs were obtained prior to treatment and weekly for 6 weeks. Minimum inhibitory concentrations (MICs) for resistant strains were assessed by E-test and National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution. Results: One week post treatment, up to 90% of children harbored macrolide-resistant strains in their oral flora. Except for azithromycin, the percentage of patients colonized by resistant organisms decreased to a rate of 17% for clarithromycin (10/60), erythromycin (2/12) and josamycin (2/12) and 33% for roxithromycin (4/12) after 6 weeks. In the azithromycin group, 85% (51/60) of patients were colonized by macrolide-resistant organisms after 6 weeks, 11.6% (7/60) of children suffered from reinfection. Conclusion: Azithromycin therapy appears to put selective pressure on the infective and native flora of children, promoting the carriage of macrolide-resistant strains.
引用
收藏
页码:251 / 256
页数:6
相关论文
共 39 条
[1]   Consequences of increasing resistance to antimicrobial agents [J].
Acar, JF ;
Goldstein, FW .
CLINICAL INFECTIOUS DISEASES, 1998, 27 :S125-S130
[2]   Pneumococcal macrolide resistance - myth or reality? [J].
Amsden, GW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (01) :1-6
[3]   Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain:: Results of a 1-year (1996-1997) multicenter surveillance study [J].
Baquero, F ;
García-Rodríguez, JA ;
de Lomas, JG ;
Aguilar, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) :178-180
[4]   Evolution of antibiotic resistance [J].
Baquero, F ;
Blazquez, J .
TRENDS IN ECOLOGY & EVOLUTION, 1997, 12 (12) :482-487
[5]   Selective compartments for resistant microorganisms in antibiotic gradients [J].
Baquero, F ;
Negri, MC .
BIOESSAYS, 1997, 19 (08) :731-736
[6]   Evolving resistance patterns of Streptococcus pneumoniae:: A link with long-acting macrolide consumption? [J].
Baquero, F .
JOURNAL OF CHEMOTHERAPY, 1999, 11 :35-43
[8]  
BOLMSTROM A, 1996, ICAAC NEW ORL
[9]  
Campbell GD, 1998, CLIN INFECT DIS, V26, P1188, DOI 10.1086/520286
[10]   The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data [J].
Carbon, C ;
Poole, MD .
JOURNAL OF CHEMOTHERAPY, 1999, 11 (02) :107-118